Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 2, Randomized, Double-Blind, Placebo-Controlled Efficacy and Safety Study of Topically Administered LUT014 in Metastatic Colorectal Cancer Patients With EGFR Inhibitor Induced Acneiform Lesions

NCT04759664 is registered in ClinicalTrials.gov with Lutris Pharma Ltd. as lead sponsor.

NCT NCT04759664
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04759664 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 2, Randomized, Double-Blind, Placebo-Controlled Efficacy and Safety Study of Topically Administered LUT014 in Metastatic Colorectal Cancer Patients With EGFR Inhibitor Induced Acneiform Lesions
Lead sponsor
Lutris Pharma Ltd.
Phase
Phase 2
Overall status
Unknown status
Start date
April 12, 2021
Completion date
May 31, 2024
Enrollment
117 (estimated)
Sites
20

Conditions

As the registry lists them; a condition with its own page is linked.

egfri induced acneiform lesions